Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 90

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Myasthenia gravis

Not recruiting

Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Study on Testosterone Undecanoate for Neuroprotection and Myelin Repair in Patients with Relapsing Remitting Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Testosterone Undecanoate
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Migraine

Not recruiting

Study on the Effectiveness of Fremanezumab for Preventing Migraines in Children and Teens Aged 6 to 17

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Fremanezumab
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Study on Long-Term Safety and Effectiveness of Vamorolone in Boys with Duchenne Muscular Dystrophy Who Completed Previous Vamorolone Studies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Vamorolone
  • Sponsor:Santhera Pharmaceuticals (Schweiz) AG

Ischaemic stroke

Not recruiting

Study on Glenzocimab for Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glenzocimab
  • Sponsor:Assistance Publique Hopitaux De Paris

Rett syndrome

Not recruiting

Study on the Safety and Tolerability of Leriglitazone for Children with Rett Syndrome

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Leriglitazone
  • Sponsor:Minoryx Therapeutics S.L.

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Migraine

Not recruiting

Study on Migraine: Effects of Fremanezumab on Brain Chemistry in Patients with and without Aura

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Fremanezumab
  • Sponsor:Medizinische Universitaet Innsbruck

Acoustic neuroma

Not recruiting

Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nimodipine
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Study on the Effects of Bosentan for Patients with Early Stage Non-Arteritic Anterior Ischemic Optic Neuropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.